drugset / Trial / NCT04322032

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389

NCT04322032

Phase 1 Unknown 34 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, fasted, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-389 in healthy volunteers.

Timeline

Start
2020-04-06
Primary completion
2020-05-12
Completion
2020-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-389 Unknown Oral
Subject D308 Unknown Oral
Subject D759 Unknown Oral